FDA Considers Easing Controls on Diabetes Drug

A panel of advisors says that the agency should loosen restrictions on the sale of a diabetes drug with a spotty clinical safety record.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, TOM VARCOA US Food and Drug Administration (FDA) advisory panel recommended yesterday (June 10) that the agency loosen restrictions on the availability of the diabetes drug Avandia, which has been linked to increased heart attack risk, in light of new evidence that the drug is safe, reported Nature.

Avandia has been the subject of controversy since 2007, when a meta-analysis of clinical trial data showed that it poses a risk to the heart. Having come to similar conclusions, in 2010 the FDA severely restricted sales of the drug, allowing access only if patients had tried every other diabetes medicine and had been made aware of the risks of taking Avandia. The drug’s sale in Europe was blocked altogether.

Then things got rather murky. An FDA analysis of one the key trials assessing heart risk—a clinical trial called RECORD, which was funded by Avandia’s maker, GlaxoSmithKline (GSK)—revealed some suspicious omissions in the data that suggested it was biased in favor of the drug. What’s more, an FDA staffer argued that that GSK had a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Dan Cossins

    This person does not yet have a bio.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide